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Abstract  
Misuse and dependence on prescribed and over the counter (OTC) codeine-combination 
analgesics is an emerging public health concern. We present a clinical case series of four 
adult patients dependent on OTC codeine combination analgesics in Ireland. Cases (two 
males/two females, aged 44–57 years) were consuming between 12 and 72 codeine-
containing tablets/day. In three cases, consumption was linked to pain, with on-going misuse 
reflecting dependence on codeine. Cases were initiated on buprenorphine-naloxone 
(Suboxone®), stabilised on doses of between 4 mg/1 mg and 14 mg/ 3.5 mg per day and 
remain on treatment without additional opioid use, as verified by drug screening reports. 
Although anecdotal, these cases show the potential of effective opioid agonist treatment 
(OAT) using buprenorphine-naloxone (Suboxone®) to successfully treat this distinct form of 
opioid dependence disorder. Optimal service provision should recognise unique patient 
profiles and needs for this form of opioid dependence and incorporate psycho-social supports.  
 
Key Words 
Codeine, opioid analgesic dependence, opioid painkiller dependence, buprenorphine-
naloxone, Suboxone® 
  
Blinded Manuscript Click here to view linked References
Dependence on over the counter (OTC) codeine containing analgesics: treatment and 
recovery with buprenorphine naloxone 
 
2 
 
Introduction  
Addiction to opioids is defined as a chronic relapsing disorder characterised by permanent 
metabolic disorder (Dole and Nywsander, 1965). Diverse treatment approaches centre on the 
support of patients dependent on opioids and include long term opioid agonist treatment 
(OAT), detoxification, relapse prevention, psychosocial interventions and therapeutic 
communities (Amato et al., 2005; 2011). The use of several therapeutic agents is paramount 
in the management, stabilisation and detoxification of such patients, and includes the oral 
administration of full or partial opioid agonists such as methadone, buprenorphine, LAAM, 
codeine or morphine (Amato et al., 2005; Gowing et al., 2011; Riksheim et al., 2014).  
 
Cochrane reviews have demonstrated strong evidence for effectiveness of methadone 
substitution treatment (Mattick et al., 2009; 2014), amid calls to scale up global availability in 
recent years (Mattick et al., 2009; Mathers et al., 2010). Methadone substitution is however 
controversial given the potential for fatal overdose, and long term and sometimes indefinite 
duration of treatment (Amato et al., 2005; Strike et al., 2013). Treatment retention is related to 
the prescribing of appropriate, individually determined and higher doses of methadone 
(Amato et al., 2005; Bao et al., 2013). Unpleasant withdrawals reported by methadone 
patients when tapering has contributed to the use of alternative therapeutic agents to support 
the patient such as clonidine, lofexidine, dihydrocodeine (DHC) and, more recently 
buprenorphine (Wright et al., 2007; Gowing et al., 2006;2009).   
 
In terms of comparing methadone and buprenorphine, Cochrane reviews have determined that 
buprenorphine is an effective medication in the maintenance treatment of heroin dependence, 
retention of patients at doses above 2mg, and suppression of illicit opioid use at doses above 
16mg based on placebo-controlled trials (Mattick et al., 2014). Mattick et al., (2014) also 
found high quality of evidence that buprenorphine was superior to placebo in treatment 
retention at all doses. However, methadone is superior to buprenorphine at patient retention, 
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with buprenorphine at flexible or low fixed doses resulting in poorer patient retention. No 
differences in effectiveness (retention and suppression of illicit opioid use) between 
methadone and buprenorphine are observed when fixed medium or high doses are used 
(Mattick et al., 2014).  Hser et al., (2014) also reported on the association of methadone with 
enhanced treatment retention when compared to buprenorphine, but with provision of 
buprenorphine related to lower continued use of illicit opioids. In terms of patient completion 
of treatment, Gowing et al., (2006; 2009) in their Cochrane Reviews found no significant 
differences between methadone and buprenorphine, but reported that buprenorphine achieves 
faster reduction of withdrawal symptoms, and is more effective than clonidine in the 
management of opioid withdrawals. Sublingual buprenorphine-naloxone may also cause less 
fatal intoxications than methadone (Soyka, 2015).   
 
Cost of treating with methadone is less than with buprenorphine (Connock et al., 2007). Maas 
et al., (2013) in their economic evaluation of buprenorphine versus methadone in opiate 
substitution treatment, emphasise that buprenorphine is appropriate if cessation of opiate use 
plus retention are primary outcomes.  Gouveia et al., (2015) in their cost –effectiveness and 
cost utility of fixed dose combination of buprenorphine-naloxone versus methadone in 
substitution treatment, concluded that the buprenorphine-naloxone combination is cost-
effective (acquisition, preparation and transport of medication, cost of dispensing, supervision 
of administration, patient monitoring and non-medical direct costs of crime related to drug 
addiction) and can potentially generate health gains measured using number of heroin free 
days per year and quality adjusted life years (QALYs) in the target patient population at a low 
cost.  Mutlu and Bilici (2015) have also recently reported on the effectiveness of outpatient 
buprenorphine-naloxone maintenance therapy in Turkey, which can be enhanced with 
incorporation of psychosocial supports.  
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Codeine dependence has emerged as recent public health concern and is underpinned by 
widespread availability for the symptomatic relief of mild to moderate pain or cough 
(UNODC, 2011; Van Hout and Norman, 2015), with an increasing evidence base highlighting 
diverse forms of misuse of and dependence on codeine containing analgesics in Australia, 
South Africa, the United Kingdom, France and the United States (Van Hout et al., 2014). The 
issue of iatrogenic opioid analgesic dependence confounds treatment pathways and recovery 
outcomes (Stannard, 2013; Marr and Hill 2015). Adverse health harms are also reported on 
excessive or high dose consumption of combination analgesics containing codeine with 
paracetamol or ibuprofen (Lambert and Close, 2005; Dutch, 2008; Evans et al., 2010; Ernest 
et al., 2010; Frei et al., 2010; Ng et al., 2011) and with increases in mortality reported 
(Pilgrim et al., 2013; Handley and Flanagan, 2014).  Increases in patient attendance of health 
services for opioid analgesic dependency are also reported, particularly in countries where 
available in over the counter (OTC) codeine containing formulations (Myers et al., 2003; 
McDonough, 2011; Stannard, 2013; Nielsen et al., 2015a).  
 
Whilst qualitative studies in the UK, South Africa, Australia and Ireland have investigated the 
experiences of individuals dependent on codeine (Nielsen et al., 2010; 2011; Nielsen et al., 
2013; Cooper, 2011, 2013; Van Hout, 2015; Van Hout et al., 2015a; b), scant attention has 
been paid to the design and provision of appropriate and specific treatment modalities for 
codeine dependence (Marr and Hill, 2015; Nielsen et al., 2015b). Studies show that 
individuals experiencing codeine dependence are different to other opioid dependent groups 
(Nielsen et al., 2011; Nielsen et al., 2015c). Patient’s often lack of recognition of their 
problematic codeine use, with a perception of themselves as ‘different’ to drug addicts, with 
stigma relating to addiction treatment (particularly methadone) and with the blurring between 
therapeutic and problematic use confounding treatment uptake (Nielsen et al., 2010; Reed et 
al., 2011; Kean, 2015).   
 
Dependence on over the counter (OTC) codeine containing analgesics: treatment and 
recovery with buprenorphine naloxone 
 
5 
 
Until recently, there is a limited evidence base to underpin best practice guidelines for OAT 
in this type of opioid dependent patient (Cooper, 2013; Conroy and Hill, 2014; Hard, 2014) 
with guidelines generally concerning treatment of illicit drug use (National Institute for 
Health and Clinical Excellence, 2007). Buprenorphine-naloxone whilst generally used for 
treatment of heroin dependence, is an effective opioid agonist treatment for prescription and 
OTC opioid analgesic dependence(Sigmon et al., 2009; Weiss et al., 2011), and is reported to 
benefit patients presenting with codeine dependence (Department of Health -England and the 
Developed Administrations, 2007; Stannard, 2013; Royal College of General Practitioners, 
2014). It has more recently been investigated for use in codeine dependence in Australia 
(Nielsen et al., 2015b). Recent case studies in the UK have also indicated successful treatment 
experiences and recovery outcomes using buprenorphine-naloxone (Hard, 2014; Conroy and 
Hill, 2014; Kean, 2015; Marr and Hill, 2015). Decisions to use buprenorphine-naloxone are 
underpinned by its safety profile compared to methadone (ceiling effect on respiratory 
depression and lower abuse potential), lack of association with QT prolongation, fewer 
symptoms of withdrawal when discontinued, and enhanced ability to continue occupational 
and social functioning (in contrast to methadone) due to greater clarity of thought (Conroy 
and Hill, 2014; New Zealand Ministry of Health, 2014; Fiellin et al., 2014; Hard, 2014).  
 
Most current data in Ireland indicates that 1.9% of patients in drug treatment reported codeine 
as a primary or secondary drug of abuse in the time period 2008-2012 (personal 
communication from the National Drug Treatment Reporting System). For patients requiring 
OAT, the most widely prescribed treatment in Ireland is methadone. At the time of writing, 
buprenorphine-naloxone (Suboxone®) is now prescribed to 77 patients in selected dispensing 
clinics in Ireland. We report four Irish cases of dependence on OTC codeine-combination 
analgesics (containing codeine-ibuprofen) and describe treatment and on-going recovery with 
buprenorphine-naloxone through a pilot feasibility project. Initiation of treatment using 
buprenorphine-naloxone was chosen for these specific cases for the following reasons; whilst 
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they often present with similar underlying issues of trauma, they are generally better 
functioning in terms of social and occupation, and are often in employment.  They generally 
dislike the sedating effect from OAT and are subsequently commenced on Suboxone® where 
available. The faster induction facilitates easier transferal to OAT, the cessation of use of 
OTC codeine containing medicines relatively easily in one day, and with easier stabilisation. 
Safe titration to a sufficient dose of methadone would have taken several weeks, during which 
time concomitant opioids are required to prevent withdrawal and with the final high dose of 
methadone potentially posing an overdose risk.  
 
Case One  
A 57-year old married healthcare professional presented to her general practitioner (GP) 
because of a single episode of haematemesis that morning. The case admitted to misuse of 
OTC codeine-ibuprofen. Her GP was aware that the case had suffered a broken wrist 3 years 
earlier and had taken codeine-ibuprofen at the time for pain. After ordering blood tests and 
satisfied that the bleed was most likely related to her high consumption of codeine-ibuprofen, 
she was referred to the local dependency/addiction service where a detailed history revealed 
the full extent of the case’s analgesic consumption, and the degree to which it had damaged 
her life. The case had been aware of her growing dependence over time, but her use escalated 
from 12 tablets per day to 24–48 tablets a day over a three-year period since the fracture. 
Aware of her problem, she reported that she ‘could not survive 1 day without taking the 
tablets’ and would visit different chemists far from her home and pay people to buy the 
tablets for her. The on-going use gave her a ‘high’ as well as experiencing dissociation from 
herself. The case neglected her appearance and her family’s needs, became estranged from 
her children and was no longer able to work.  
 
The case was counselled and agreed to begin opioid agonist treatment (OAT). At the time, 
treatment with buprenorphine-naloxone was available through a pilot feasibility project in 
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Ireland. To begin, the case did not consume codeine for 24 hours. Treatment initiation was 
uneventful—the case experienced discomfort for most of the day and was stabilised on a 4 
mg/1 mg dose of buprenorphine-naloxone. As part of her on-going recovery, she speaks to a 
counsellor every two weeks, and her doctor once a month. After four years of OAT, all drug 
screens have been negative. She continues to receive supervised buprenorphine-naloxone 
from the local pharmacy. She has gradually reduced her dose over the last 2 years and is 
currently stable with the expectation of treatment discontinuation in the near future. Her self-
confidence has returned over time, and the case has become reconciled with her family.  
 
Case Two  
A 44-year old divorced, working mother was contacted by her GP after he received questions 
from a pharmacist about the case’s high-volume use of codeine-ibuprofen and from the same 
case’s employer about the case’s sick notes. The case came into the practice and after hearing 
her GP’s concerns, admitted altering the GP’s letters to cover up her high volume use of OTC 
analgesics. Her GP immediately recognised her dependence on codeine and referred her to 
addiction services. On presentation to the addiction clinic, the case described a 10-year 
history of debilitating migraines and depression. Initially prescribed co-codamol for a short 
period, she regularly used OTC co-codamol and codeine-ibuprofen on top of her prescription. 
After a traumatic personal event (the end of her marriage), the case was diagnosed with 
depression and prescribed antidepressants. During this time she began to escalate her use of 
OTC drugs. On a normal day she would consume 36 tablets, travelling to different 
pharmacies every day to avoid suspicion and took her mother or friend’s prescriptions for 
opioid-containing medications whenever possible. The addiction clinic discussed with her and 
recommended buprenorphine-naloxone, which was available through the pilot project in 
Ireland.  
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At commencement of OAT, the case was attending the local community mental health team 
and was under the care of a psychiatrist and prescribed venlafaxine for depression, 
propranolol for migraine and omeprazole for a peptic ulcer. She was initiated onto 
buprenorphine-naloxone after 24 hours without codeine consumption and although concerned 
about withdrawal, it was less severe than she anticipated with symptoms limited to itching, 
sweating, and headache. After stabilising on a 14 mg/3.5 mg dose, her migraines largely 
resolved and soon after treatment, she was able to stop antidepressant treatment. The case is 
currently attending the addiction clinic twice a week with on-going psychosocial counselling. 
She reports ‘finally I feel normal again and have the energy to get through the day and get 
on with things’ and has returned to work. Within the next few months, the pathway from 
maintenance to detoxification will be addressed with this case. 
 
Case Three  
A 45-year old single man with a past history of alcohol dependence and on-going 
benzodiazepine use with comorbid severe personality difficulties had a long history of OTC 
codeine misuse that was causing life-threatening morbidity. He had suffered a perforated 
ulcer in 2012, which required surgical repair. In addition he developed pancreatitis and partial 
Addison’s disease due to dihydrocodeine misuse. In early 2014, he was found to have three 
chronic ulcers—one gastric ulcer and two in the duodenal. He had multiple surgical 
admissions due to the severity of his epigastric pain and GI bleeding. Typically his symptoms 
would quickly improve, but he continued to misuse OTC analgesics on discharge. In view of 
this a partial or total gastrectomy was being considered. 
 
Prior treatments had failed. He had undergone several community and inpatient 
detoxifications from codeine but quickly relapsed on each occasion. Several attempts to 
stabilise him on a maintenance dose of codeine in the community had also failed. In 2010, a 
trial of buprenorphine was initially successful for three months but due to benzodiazepeine 
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use on top, he overdosed on benzodiazepines, was hospitalised and buprenorphine treatment 
was withdrawn. Due to the extent of his ulceration, the severity of his pain and the chronic 
nature of his addiction, the best treatment course were not obvious. He did not want gastric 
surgery and understood that on-going misuse of OTC analgesics would shorten his life. He 
wished a further trial on OAT. He understood that buprenorphine/naloxone would be 
dispensed from the community pharmacy with supervised daily consumption, and that the 
treatment would also involve regular attendance with a keyworkers for psychosocial support. 
He was admitted to the addictions unit in May 2014 to manage OAT initiation, which was 
successful. He was stabilised, and is currently maintained on a dose of 12 mg/3 mg 
buprenorphine-naloxone. His urine drug screens have remained consistently opiate and 
benzodiazepine free although cannabis positive. He has never presented sedated or 
intoxicated, attends regularly for his script and has had a great reduction in gastric pain He 
has had two very brief admissions with gastritis which settled quickly with conservative 
management. 
 
Case Four  
A 44-year old divorced, homeless man presented to his community drug service in a poor 
physical health. Originally prescribed codeine for back pain, over the course of several years 
he began using escalating amounts of OTC codeine-ibuprofen analgesics, with peak 
consumption reaching 72 tablets/day. He found that codeine sedated the depression he was 
experiencing with losing his job, but he began to consume too much alcohol and eventually 
his family situation broke down and he became homeless. During his time in homeless 
services he had also begun using other substances including hypnotics. The case had a pre-
existing heart condition which was exacerbated by his codeine-ibuprofen consumption.  
 
He was assessed and referred to the National Drug Treatment Centre, where he underwent 
psychiatric assessment, urine screening and was initiated onto buprenorphine-naloxone in 
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conjunction with psychosocial interventions. He was initiated and stabilised on a maintenance 
dose of 8 mg/2 mg daily with on-going counselling. Soon after, he was referred for 
rehabilitation. After 11 months of buprenorphine-naloxone treatment, the case was taking 
unsupervised doses and attempted to detoxify from treatment without medical supervision. At 
day 6, he relapsed. He revealed to his key worker that he had not fully disclosed his excessive 
alcohol intake or his intermittent misuse of cough bottles. The case was counselled and again 
initiated onto buprenorphine-naloxone. He is currently stabilised on a dose of 12mg daily 
with on-going psychosocial support. Currently he is still experiencing misuse issues with 
cannabis and benzodiazepines.  
 
Discussion  
The heterogeneous nature of codeine misuse and varying profile of treatment case’s for 
codeine dependence is evident, given their distinct characteristics from other opiate using 
populations, and they often require alternative forms of treatment provision and therapeutic 
modalities (Nielsen et al., 2011; Hard, 2014; Nielsen et al, 2015a). These four cases from 
Ireland highlight the wide spectrum of people who become dependent on OTC codeine-
combination analgesics, from a male case with a long history of complex and multiple 
addictions and personality difficulties and with a strong family history of addiction, to 
middle-aged husbands and wives whose initial consumption of codeine was linked to a 
legitimate pathology. In all four cases, the dependence was associated with codeine-ibuprofen 
combination analgesics, attending multiple pharmacies to obtain tablets, persistent 
psychological problems that disrupted normal life and finally significant morbidity linked to 
the misuse. Similar findings are reported elsewhere (Nielsen et al., 2010; 2011; Nielsen, 
Cameron & Pahoki, 2013; Cooper, 2011, 2013; Van Hout, 2015; Van Hout et al., 2015a;b).  
The cases of GI haemorrhage and ulcer perforation also align closely with previous 
descriptions of codeine-ibuprofen dependency (Lambert and Close, 2005; Dutch, 2008; Evans 
et al., 2010; Ernest et al., 2010; Frei et al., 2010; Ng et al., 2011).   
Dependence on over the counter (OTC) codeine containing analgesics: treatment and 
recovery with buprenorphine naloxone 
 
11 
 
Codeine has lower potency than other opioids (for example heroin, methadone, morphine, 
oxycodone), with codeine dependent individuals using lower doses of opioids when compared 
to oral morphine equivalents (Nielsen et al., 2015c). Nielsen et al., (2015b) highlight that 
whilst lower potency of codeine is consumed, buprenorphine dose requirements for codeine 
dependence cannot be assumed to generalise that of heroin dependence, despite evidence for 
consistently higher doses of buprenorphine estimations based on dose of codeine consumed, 
and comparability to that of heroin and more potent prescription opioid treatment. This 
Australian study revealed concerns that clinicians using standard opioid dose conversion 
calculations (Fine and Portenoy, 2009) are at risk of underestimating required dose of 
buprenorphine, and can potentially reduce clinical outcomes (Doran et al., 2005; Mattick et 
al., 2014). Individual dose titration is best practice (Gowing et al., 2014), with high dose 
buprenorphine appearing to be well tolerated and safe (Nielsen et al., 2015b). The 
recommendation is that codeine dependent patients receive doses similar to that of other 
opioid dependent people (Nielsen et al., 2012) in the 16-32 mg/day range (Fareed et al., 
2012).  Higher doses may also improve retention (Fareed et al., 2012). 
 
Although anecdotal, these cases are typical of other cases of codeine dependence we have 
treated. For the patients described here, OAT using buprenorphine-naloxone has been 
successful, with patients returning to a better psychological state and functioning again within 
their families and/or within society. They highlight the problem of OTC codeine combination 
analgesic dependence and show the potential of effective OAT using buprenorphine-naloxone 
coupled with psychosocial counselling to successfully treat this form of opioid dependence.  
This is supported by case studies conducted in the UK (Conroy and Hill, 2014; Hard, 2014; 
Kean, 2015) which have highlighted the need for buprenorphine-naloxone programming 
within a holistic behaviour change programme with incorporated psycho-social intervention 
and recovery supports.  
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Conclusion 
We underscore how opioid based prescription/OTC medication dependence warrants 
alternative low threshold service provision in primary care, and one that is tailored to the 
differences between iatrogenic opioid dependence and that of illicit opioids (Marr and Hill, 
2015). Additional differences pointing to the need for buprenorphine-naloxone as treatment 
options are underpinned by demographic and substance use characteristics of codeine 
dependents (Nielsen et al., 2011; Nielsen et al., 2015c). Distinguishing iatrogenic dependence 
as opposed to that of illicit drug use also reduces stigma and facilitates enhanced treatment 
entry for pain patients (Marr and Hill, 2015). The cases highlighted the need for prescriber 
and pharmacist assessment of risk of developing codeine dependence through routine 
screening (Hard, 2014). Primary care physicians are advised to consider potential iatrogenic 
opioid dependence in patients (Hard, 2014). In 2010, the Irish pharmacy regulator 
(Pharmaceutical Society of Ireland) enforced new regulations to regulate the safe supply of 
non-prescription combination products containing codeine and paracetamol, aspirin or 
ibuprofen for supply only as ‘second line’ products for pain relief; and with comprehensive 
patient advice provided around correct use for short-term use (for example no longer than 
three days), and with products inaccessible to the public for self-selection.  
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